Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Eli Lilly Says It Will Launch 20 New Products Through 2023
Eli Lilly Offers Outline of Potential to Launch 20 New Products in 10 Years
$6 Biopharma Stock Is For The Dogs! Why That Is A Good Thing For Investors (Seeking Alpha)

In a report published Friday, Goldman Sachs Group reiterated its Sell rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $39.00 to $42.00.

Goldman Sachs noted, “We reiterate our Sell rating on LLY shares (relative to our Attractive coverage view on Pharma) and would take profits on recent strength driven by what we believe is a solanezumab hope-induced trade, which we see as premature. Based on our analysis, LLY shares already reflect $7 bn in Sola optionality value and a 50% probability of sola success, driven by the hint of efficacy seen in a pooled analysis of both studies in secondary endpoints. Data at ANA on Oct 8 will be a key to either supporting or significantly challenging that view. We are skeptical about a meaningful benefit and at the very best, expect that LLY will have to run another confirmatory Phase 3 clinical trial for 18 months in mild patients if the efficacy signal is based on a meaningful clinical benefit. This pushes the timeline out by 3-4 years.”

Eli Lilly & Co. closed on Thursday at $47.15.

Latest Ratings for LLY

DateFirmActionFromTo
May 2016Leerink SwannMaintainsOutperform
May 2016Credit SuisseMaintainsOutperform
Apr 2016Societe GeneraleInitiates Coverage onHold

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!